News & Views
Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised…
Read more
Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA…
Read more
Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50…
Read more
Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of…
Read more
Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public…
Read more
Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology…
Read more
News,
Telix is pleased to announce today that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of Telix Pharmaceuticals Limited as Non-Executive…
Read more
Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd…
Read more
Telix is pleased to announce a licence agreement collaboration with Abzena plc (Abzena) for its prostate-specific membrane antigen antibodies…
Read more
Telix is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma SAS…
Read more